Research Article
Adjuvant Therapy: Melanoma
Table 1
Phase II trials of IFN-α for metastatic melanoma.
| Study reference | No. of enrolled patients (followup) | Therapy and IFN subspecies | Dose—treatment arm (MU/m2) | Schedule—treatment arm | ORR | CR | PR |
| Ernstoff et al. 1983 [82] | 17 | α2b | 10–100 | 5 d/week × 1 month | N/A | N/A | 2 |
| Creagan et al. 1984 [83] | 23 | α2a | 50 | Thrice weekly × 12 weeks | 20 | 1 | 5 |
| Creagan et al. 1985 [84] | 350 | α2a + cimetidine | 50 | Thrice weekly × 12 weeks | 23 | 0 | 8 |
| Creagan et al. 1984 [85] | 31 | α2a | 12 | Thrice weekly × 12 weeks | 23 | 3 | 4 |
| Legha et al. 1987 [86] | 62 | α2a | 1st arm—escalating (3–36 × 106 U/d) 2nd arm—fixed dose (18 × 106 U/d) | 1st arm—daily during induction followed by thrice weekly 2nd arm—thrice weekly | 1st—12.9% 2nd—16.1% | 1st 0 2nd 0 | 1st—9.7% 2nd—6.5% |
| Hersey et al. 1985 [87] | 200 | α2a | 15–50 | Thrice weekly | 10 | 2 | 0 |
| Neefe et al. 1990 [88] | 97 | α2a | Escalating: 3 to 36 × 106 U | Daily for 10 days then 70 days total | 8 | 6 | 2 |
| Dorval et al. 1986 [89] | 22 | α2b | 10 | Thrice weekly | 24 | 2 | 4 |
| Coates et al. 1986 [90] | 15 | α2a | 20 | 5 d/week every 2 weeks | 0 | 0 | 0 |
|
|